Skip to main content

Govt proposes abolishing clinical trials on proven drugs

Abolishing clinical trials for proven drugs will also lower the cost of medicines in India. Photo: Bloomberg

The move to abolish clinical trials of proven drugs will reduce time taken to introduce new drugs in India to just 45 days from 5-6 years.

In a move aimed at speeding up the availability of new drugs, the government has proposed doing away with clinical trials for drugs that have proved their efficacy in developed markets.

According to a proposed new set of rules, a part of which has been reviewed by Mint, the government suggested waiving local clinical trials for drugs that have not had any major adverse effects on patients.

These drugs should have been approved and marketed for at least two years in the European Union, UK, US, Australia, Canada and Japan. The ministry of health and family welfare has sent the draft proposal to the ministry of law and justice for vetting before it can be notified.

The move is expected to reduce the time taken by a company to introduce new drugs in the market from 5-6 years to as few as 45 days. According to the drug regulator, the move will also lower the cost of drugs.

"This will end unnecessary repetition of trials and speed up the availability of new drugs in the country—a win-win situation for both the industry and consumers," Drug Controller General of India G.N. Singh said in a phone interview.

Lengthy clinical trial and approval procedures deprive Indians of advanced medicines, said R.K. Vats, additional secretary in the health ministry.

Continue reading...

ᐧ

Comments

Post a Comment

Popular posts from this blog

Isotretinoin in India: A tragedy in the offing

Isotretinoin in India: A tragedy in the offing Wednesday, March 28, 2007 08:00 IST  Seema Thakral Isotretinoin is the drug of choice for severe calcitrant cystic acne vulgaris, which often causes scarring and depression from disfigurement. Isotretinoin has been called "the greatest medical advance of the 1980's." A majority of patients with acne are permanently cleared after a four to five months course of treatment. It has also been used off-label for a variety of oncology uses including: cervical cancer, head and neck cancer, squamous cell cancer of the skin, juvenile chronic myelogenous leukemia (CML), and neuroblastoma. However, the drug is a proved teratogen and carries a significant risk of birth defects, if it taken during pregnancy. Birth defects, which have been documented following isotretinoin exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. There is an increased ris
Post a Comment
Read more

The Connection Between Sedatives and Fractures in Elderly Patients

Johns Hopkins Health Alerts: Prescription Drugs The Connection Between Sedatives and Fractures in Elderly Patients All drugs have potential side effects. Indeed, at some point you've probably squinted down the laundry list of possible side effects on the package insert of your medications. Common drug-related side effects include blurred vision, drowsiness, dizziness, dry mouth, heart palpitations, erectile dysfunction, memory impairment, and nervousness. Fortunately, many of these drug side effects occur in only small numbers of people. Now researchers have called into question the connection between sedatives which can cause dizziness and the potential for falls in elderly patients. They point out that well-meant policies discouraging sedative use in older people to prevent falls and fractures may not be necessary. Starting in 1989, New York State required doctors to fill out prescriptions in triplicate for benzodiazepines, the most widely used class of sedativ
Post a Comment
Read more

Contract Research Organization Services (CROs) Market Worth 56.34 Billion USD by 2023

 According to a new market research report "Contract Research Organization Services (CROs) Market by Type (Discovery, CMC, Preclinical, Clinical Research, Laboratory Services), Therapeutic Area (Oncology, CNS, Cardiovascular), End User (Pharmaceuticals & Medical Device) - Global Forecast to 2023", published by MarketsandMarkets™, the global market is projected to reach USD 56.34 Billion by 2023 from USD 39.13 Billion in 2018, at a CAGR of 7.6%. Continue reading here ᐧ
Post a Comment
Read more